恩替卡韦抗病毒治疗失代偿期乙肝肝硬化的疗效观察

Effect of Entecavir Antiviral Therapy on Decompensated Hepatitis B Cirrhosis

目的探讨恩替卡韦抗病毒治疗失代偿期乙肝肝硬化临床效果,寻找一个疗效更确切的治疗失代偿期乙肝肝硬化的临床方案,由此能够增强其预后质量。方法将本院收治的35例失代偿期乙肝肝硬化患者随机分为研究组(18例)、对照组(17例),在常规治疗基础上,前者给予恩替卡韦治疗,后者给予阿德福韦酯治疗,对比两组患者肝功能变化、不良反应发生率及HBV-DNA转阴率。结果①肝功能:治疗前,两组的TBLL、ALT、ALB水平对比不存在明显差异性(P>0.05);治疗后,TBLL、ALT、ALB水平相比,研究组优于对照组P<0.05;②不良反应:研究组11.1%显著低于对照组41.2%,差异显著P<0.05;③HBV-DNA转阴率:研究组88.9%明显高于对照组52.9%,差异为P<0.05,具有统计学意义。结论治疗失代偿期乙肝肝硬化过程中,应用恩替卡韦抗病毒治疗可有效改善患者肝功能,抗病毒能力强,有利于提升HBV-DNA转阴率,同时安全性较高,临床应用价值显著。

Objective To investigate the clinical effect of entecavir in the treatment of decompensated hepatitis B cirrhosis.Methods 35 patients with decompensated hepatitis b cirrhosis in our hospital were randomly divided into study group (18 cases) and control group (17 cases).on the basis of routine treatment,the former was treated with entecavir and the latter with adefovir ester to compare the changes of liver function,the incidence of adverse reactions and the rate of HBV-DNA conversion.Results ①Liver function:after treatment,the TBLL、ALT、ALB level of the study group was better than the control group P<0.05.② Adverse reactions:the study group 11.1% significantly lower than the control group 41.2%,the difference significantly,P<0.05.③ HBV-DNA conversion rate:the study group 88.9% significantly higher than the control group 52.9%,the difference is P<0.05,with statistical significance.Conclusion During the treatment of decompensated hepatitis B cirrhosis,entecavir antiviral therapy can effectively improve the liver function of patients,improve the rate of HBV-DNA conversion,at the same time,the safety is high,and the clinical application value is remarkable.